This discovery suggests that monitoring nATPCD4 and sATPCD4 concentrations in peripheral blood prior to treatment could be instrumental in predicting the likelihood of irAEs in advanced NSCLC patients who are undergoing therapy with PD-1/PD-L1 inhibitors. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.